

Oscar B Lahoud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3971514/publications.pdf>

Version: 2024-02-01

27
papers

455
citations

933447

10
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

680
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
2	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	7.1	63
3	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
4	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	4.6	50
5	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	12.8	41
6	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	1.4	34
7	Managing multiple myeloma in elderly patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1300-1311.	1.3	18
8	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 198-200.	0.4	17
9	High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 42.	4.0	13
10	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	1.2	11
11	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
12	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 204-208.	2.0	10
13	Artesunate-related fever and delayed hemolysis in a returning traveler. <i>IDCases</i> , 2015, 2, 63-65.	0.9	8
14	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8
15	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. <i>Blood</i> , 2021, 138, 1644-1644.	1.4	7
16	Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 654-656.	2.4	3
17	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.	7.0	2
18	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2040-2046.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 3271-3271.	1.4	1
20	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
21	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
22	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	1.3	1
23	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2760-2761.	1.3	1
24	Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 5865-5865.	1.4	0
25	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
26	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). <i>Blood</i> , 2020, 136, 8-10.	1.4	0
27	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 485.e1-485.e6.	1.2	0